Immune modulation after total hip surgery

被引:5
作者
Bastian, D.
Sun, J.
Krohn, C. Danckert
Reikeras, O. [1 ]
机构
[1] Natl Hosp Norway, Radiumhosp Med Ctr, Dept Orthopaed, NO-0027 Oslo, Norway
[2] Natl Hosp Norway, Radiumhosp Med Ctr, Inst Surg Res, NO-0027 Oslo, Norway
[3] Natl Hosp Norway, Radiumhosp Med Ctr, Dept Anaesthesiol, NO-0027 Oslo, Norway
基金
美国国家科学基金会;
关键词
interleukin-6; immune response; tumor necrosis factor-alpha; orthopedic trauma;
D O I
10.1159/000104400
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Major trauma affects the immune system, and immunosuppression may render the patients susceptible to septic complications. The purpose of this study was to investigate lipopolysaccharide (LPS)-induced releases of tumor necrosis factor-alpha ( TNF-alpha) and interleukin-6 (IL-6) in whole blood in patients undergoing total hip replacement. Methods: Seven patients ( 6 females) who underwent elective total hip replacement were included. Ex vivo LPS-induced releases of TNF-alpha and IL-6 were measured in a whole blood assay at days 1, 6, 9 and 12 postoperatively, using low- and high-dose LPS incubation. At the same time, white blood cell counts were analyzed. Results: The amount of TNF-alpha release was significantly reduced at days 6 and 12. Compared to monocyte counts,TNF-alpha release was significantly decreased also at day 9 in low- and high-dose LPS stimulation. IL-6 in plasma was significantly increased at day 1 and normalized thereafter. There were no differences in LPS-induced IL-6 levels compared to the levels before surgery. Conclusion: This in vivo/ex vivo study shows a reduced capacity of whole blood to release LPS-induced TNF-alpha at day 6 through to day 12 after major orthopedic surgery. Attenuated TNF-alpha release may contribute to an increased postoperative susceptibility to gram-negative sepsis. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:296 / 302
页数:7
相关论文
共 43 条
[1]
EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]
FAS LIGAND MEDIATES ACTIVATION-INDUCED CELL-DEATH IN HUMAN T-LYMPHOCYTES [J].
ALDERSON, MR ;
TOUGH, TW ;
DAVISSMITH, T ;
BRADDY, S ;
FALK, B ;
SCHOOLEY, KA ;
GOODWIN, RG ;
SMITH, CA ;
RAMSDELL, F ;
LYNCH, DH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (01) :71-77
[3]
Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis [J].
Astiz, M ;
Saha, D ;
Lustbader, D ;
Lin, R ;
Rackow, E .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, 128 (06) :594-600
[4]
BADGER AM, 1994, CIRC SHOCK, V44, P188
[5]
Interleukin-6 in the injured patient marker of injury or mediator of inflammation? [J].
Biffl, WL ;
Moore, EE ;
Moore, FA ;
Peterson, VM .
ANNALS OF SURGERY, 1996, 224 (05) :647-664
[6]
Sir Isaac Newton, sepsis, SIRS, and CARS [J].
Bone, RC .
CRITICAL CARE MEDICINE, 1996, 24 (07) :1125-1128
[7]
Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes [J].
Brandtzaeg, P ;
Osnes, L ;
Ovstebo, R ;
Joo, GB ;
Westvik, AB ;
Kierulf, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) :51-60
[8]
PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J].
CASEY, LC ;
BALK, RA ;
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :771-778
[9]
MULTIPLE ORGAN FAILURE - PATHOPHYSIOLOGY AND POTENTIAL FUTURE THERAPY [J].
DEITCH, EA .
ANNALS OF SURGERY, 1992, 216 (02) :117-134
[10]
Dimofte G, 2001, Rev Med Chir Soc Med Nat Iasi, V105, P493